Novo Nordisk
NVO
#110
Rank
A$260.49 B
Marketcap
A$59.11
Share price
-3.12%
Change (1 day)
-19.09%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): A$5.75

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is A$5.91. In 2025 the company made an earnings per share (EPS) of A$5.32 an increase over its 2024 EPS that were of A$4.91.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$5.757.95%
2025A$5.328.48%
2024A$4.91
2016A$1.67

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.06-82.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$46.31 682.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.97-49.81%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
A$6.78 14.55%๐Ÿ‡บ๐Ÿ‡ธ USA